Expression of IFN-β enhances both efficacy and safety of oncolytic vesicular stomatitis virus for therapy of mesothelioma

Cancer Research

Volumn 69, Issue 19, 2009, Pages 7713-7720

  Willmon, Candice L ^a   Saloura, Vassiliki ^c   Fridlender, Zvi G ^c   Wongthida, Phonphimon ^a   Diaz, Rosa Maria ^a   Thompson, Jill ^a   Kottke, Timothy ^a   Federspiel, Mark ^a   Barber, Glen ^d   Albelda, Steven M ^c   Vile, Richard G ^a,b  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF MIAMI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; ONCOLYTIC VESICULAR STOMATITIS VIRUS; ONCOLYTIC VIRUS; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; ARTICLE; CANCER GENE THERAPY; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFICACY; DRUG SAFETY; HUMAN; HUMAN CELL; MESOTHELIOMA; MONOTHERAPY; MOUSE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; TRANSGENE; TUMOR IMMUNITY; VESICULAR STOMATITIS VIRUS; VIRAL GENE DELIVERY SYSTEM; VIRUS REPLICATION;

ANIMALS; CELL LINE, TUMOR; EPITOPES, T-LYMPHOCYTE; GENE THERAPY; HUMANS; INTERFERON-BETA; MESOTHELIOMA; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, SCID; NERVOUS SYSTEM DISEASES; ONCOLYTIC VIROTHERAPY; T-LYMPHOCYTES; VESICULOVIRUS;

EID: 70350230280     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-1013     Document Type: Article

References (28)

1. Robinson BW, Lake RA. Advances in malignant mesothelioma.[see comment]. N Engl J Med 2005;353:1591-1603
2. Kirn D, Martuza RL, Zwiebel J. Replication-selective virotherapy for cancer: biological principles, risk management and future directions. Nat Med 2001;7:781-787 (Pubitemid 32691631)
3. Parato KA, Senger D, Forsyth PA, Bell JC. Recent progress in the battle between oncolytic viruses and tumours. Nat Rev Cancer 2005;5:965-976 (Pubitemid 41766784)
4. Diaz RM, Galivo F, Kottke T, et al. Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus. Cancer Res 2007;67:2840-2848 (Pubitemid 46548974)
5. Fernandez M, Porosnicu M, Markovic D, Barber GN. Genetically engineered vesicular stomatitis virus in gene therapy: application for treatment of malignant disease. J Virol 2002;76:895-904. (Pubitemid 34033386)
6. Barber GN. Vesicular stomatitis virus as an oncolytic vector. Viral Immunol 2004;17:516-527 (Pubitemid 40054231)
7. Barber GN. VSV-tumor selective replication and protein translation. Oncogene 2005;24:7710-7719
8. Lichty BD, Power AT, Stojdl DF, Bell JC. Vesicular stomatitis virus: re-inventing the bullet. Trends Mol Med 2004;10:210-216 (Pubitemid 38581793)
9. Balachandran S, Barber GN. Vesicular stomatitis virus (VSV) therapy of tumors. IUBMB Life 2000;50:135-138
10. Stojdl DF, Lichty B, Knowles S, et al. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med 2000;6:821-825 (Pubitemid 30469434)
11. Stojdl DF, Lichty BD, tenOever BR, et al. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 2003;4:263-275
12. Balachandran S, Porosnicu M, Barber GN. Oncolytic activity of vesicular stomatitis virus is effective against tumors exhibiting aberrant p53, Ras, or myc function and involves the induction of apoptosis. J Virol 2001;75:3474-3479 (Pubitemid 32225911)
13. Ebert O, Harbaran S, Shinozaki K, Woo SL. Systemic therapy of experimental breast cancer metastases by mutant vesicular stomatitis virus in immune-competent mice. Cancer Gene Ther 2005;12:350-358 (Pubitemid 40411194)
14. Lichty BD, Stojdl DF, Taylor RA, et al. Vesicular stomatitis virus: a potential therapeutic virus for the treatment of hematologic malignancy. Hum Gene Ther 2004;15:821-831 (Pubitemid 39244837)
15. Lun X, Senger DL, Alain T, et al. Effects of intravenously administered recombinant vesicular stomatitis virus (VSV(δM51)) on multifocal and invasive gliomas. J Natl Cancer Inst 2006;98:1546-1557 (Pubitemid 44680906)
16. Shinozaki K, Ebert O, Woo SL. Eradication of advanced hepatocellular carcinoma in rats via repeated hepatic arterial infusions of recombinant VSV. Hepatology 2005;41:196-203. (Pubitemid 40066398)
17. Stojdl DF, Abraham N, Knowles S, et al. The murine double-stranded RNA-dependent protein kinase PKR is required for resistance to vesicular stomatitis virus. J Virol 2000;74:9580-9585 (Pubitemid 30746808)
18. Sterman DH, Albelda SM. Advances in the diagnosis, evaluation, and management of malignant pleural mesothelioma. Respirology 2005;10:266-283 (Pubitemid 41025602)
19. Odaka M, Sterman DH, Wiewrodt R, et al. Eradication of intraperitoneal and distant tumor by adenovirus-mediated interferon-β gene therapy is attributable to induction of systemic immunity. Cancer Res 2001;61:6201-6212 (Pubitemid 32762558)
20. Odaka M, Wiewrodt R, DeLong P, et al. Analysis of the immunologic response generated by Ad.IFN-β during successful intraperitoneal tumor gene therapy. Mol Ther 2002;6:210-218 (Pubitemid 36336128)
21. Obuchi M, Fernandez M, Barber GN. Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity. J Virol 2003;77:8843-8856 (Pubitemid 36936096)
22. Ahmed CM, Wills KN, Sugarman BJ, et al. Selective expression of nonsecreted interferon by an adenoviral vector confers antiproliferative and antiviral properties and causes reduction of tumor growth in nude mice. J Interferon Cytokine Res 2001;21:399-408.
23. Brin E, Atencio I, Helmich BK, Maneval D, Laface D. Adenovirus delivery provides extended interferon-α exposure and augments treatment of metastatic carcinoma. Cancer Gene Ther 2006;13:664-675 (Pubitemid 44264471)
24. Sterman DH, Recio A, Carroll RG, et al. A phase I clinical trial of single-dose intrapleural IFN-β gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses.[erratum appears in Clin Cancer Res. 2007 Sep 1;13:5226 Note: Kanther, Michelle [added]]. Clin Cancer Res 2007;13:4456-4466
25. Kruklitis RJ, Singhal S, Delong P, et al. Immuno-gene therapy with interferon-β before surgical debulking delays recurrence and improves survival in a murine model of malignant mesothelioma. J Thorac Cardiovasc Surg 2004;127:123-130 (Pubitemid 38160475)
26. Davis MR, Manning LS, Whitaker D, Garlepp MJ, Robinson BW. Establishment of a murine model of malignant mesothelioma. Int J Cancer 1992;52:881-886 (Pubitemid 23009503)
27. Linardakis E, Bateman A, Phan V, et al. Enhancing the efficacy of a weak allogeneic melanoma vaccine by viral fusogenic membrane glycoprotein-mediated tumor cell-tumor cell fusion. Cancer Res 2002;62:5495-5504
28. Prehn RT. Two competing influences that may explain concomitant tumor resistance. Cancer Res 1993;53:3266-3269